{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-23-000007","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.963004+00:00","generated_at":"2026-06-18T11:43:22.032073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics reports FY2022 net loss of $19.2M; advances TTP399 toward Phase 3","bullets":["Net loss attributable to shareholders was $19.2M ($0.26/share) for FY2022 vs $13.0M ($0.21/share) in FY2021.","Cash and cash equivalents at Dec 31, 2022: $12.1M, down from $13.4M a year earlier.","Received ~$12.0M from G42 Investments in Feb 2023 via early promissory note payment at 3.75% discount.","Appointed Steven Tuch as EVP/CFO (Dec 2022) and Elizabeth Keiley as EVP/General Counsel (Feb 2023).","Preparing to initiate first of two Phase 3 trials of TTP399 for Type 1 diabetes in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-23-000007","json":"https://secwatch.observer/filing/0001641489-23-000007.json","markdown":"https://secwatch.observer/filing/0001641489-23-000007.md","text":"https://secwatch.observer/filing/0001641489-23-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/0001641489-23-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/vtvt-20230306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:43:22.032073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3040d81397876f0263b297ed57c53b44d71d2d9","claim":"vTv Therapeutics Inc. reported the fourth quarter and year ended December 31, 2022 results: net income Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba, EPS $0.06 per basic share.","evidence_excerpt":"vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/0001641489-23-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss attributable to vTv shareholders for the three months ended December 31, 2022, was $4.7 million or $0.06 per ba"},{"label":"EPS","value":"$0.06 per basic share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}